Background: With rapid developments of single-cell sequencing and multi/trans-omics, clinical single-cell biomedicine is a new and emergent discipline to integrate single-cell molecular and clinical phenomes and uncover new disease-specific diagnosis and therapy. Aims: The journal of Clinical and Translational Medicine (CTM) launches the first CTM initiative of Clinical Single-Cell Biomedicine (cscBioMed) to promote the discovery and development of single-cell-based biology and medicine, speed the translation from single-cell biology into clinical application, and improve early diagnosis and therapy for human diseases. Materials & Methods: The cscBioMed initiative is speeding translational processes from circulating single-cell RNA sequencing (scRNA-seq) into routine measures in clinical biochemistry of hematology, from spatial transcriptomics into single-cell pathology, from single-cell-based biomarkers and targets into clinical diagnostics and target drugs. Conclusion: With a clear goal, we expect that cscBioMed will benefit the human health by establishing a clinical single-cell dynamic monitoring and early predicting system and by improving diagnosis and treatment.

Original languageEnglish
Article numbere168
JournalClinical and Translational Discovery
Issue number1
StatePublished - Feb 2023


Dive into the research topics of 'Initiative of clinical single-cell biomedicine in clinical and translational medicine'. Together they form a unique fingerprint.

Cite this